Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Post by bailmeouton Feb 14, 2014 8:06am
233 Views
Post# 22208871

Oh Yeah :)

Oh Yeah :)Microbix reports first quarter profit4 minutes ago by CNW Group

Revenue Doubles on Continuing Strong Customer Demand

Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reported financial results for its first quarter ending December 31, 2013.

In the first quarter, Microbix reported revenue of $1,927,885, more than double the revenue of $904,413 for the same period in 2013. The higher revenue was primarily due to continued growth in customer demand for virology products including significant new business from an existing customer, as well as a favourable currency impact. Total expenses for the first quarter were $888,778 compared to $1,039,117 for the same quarter in 2013 or a 14% reduction, primarily due to various cost savings initiatives implemented in the past year. Operating income for the first quarter was $214,406 compared to a loss of $629,505 for the same quarter last year.

Vaughn C. Embro-Pantalony, President and Chief Executive Officer remarked, "Our strong first quarter operating results compared to last year, and our consistently strong financial performance in the last two quarters, highlight the significant profitable turnaround that our Company has experienced in the past year. I am confident that we have established a solid foundation for continued success in 2014."

Bullboard Posts